NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity.

Aurelie HeraultJudy MakJosefa de la Cruz-ChuhMichael A DillonDiego EllermanMaryAnn GoEly CosinoRobyn ClarkEmily CarsonStacey YeungMelanie PicheryMylène GadorEugene Y ChiangJia WuYuxin LiangZora ModrusanGautham GampaJawahar SudhamsuChristopher C KemballVictoria CheungThi Thu Thao NguyenDhaya SeshasayeeRobert PiskolKlara TotpalShang-Fan YuGenee LeeKatherine R KozakChristoph SpiessKevin B Walsh

Published in: Cancer immunology, immunotherapy : CII (2024)

We demonstrate that targeting NKG2D with bispecific antibodies (BsAbs) is an effective approach to augment NK and CD8+ T cell antitumor immune responses. Given the large number of ongoing clinical trials leveraging NK and T cells for cancer immunotherapy, NKG2D-bispecifics have broad combinatorial potential.

Keyphrases

nk cells
clinical trial
immune response
natural killer cells
cancer therapy
toll like receptor
risk assessment
drug delivery
inflammatory response